ArticleJournal of neuropathology and experimental neurology2026
Effects of concurrent neuropathologies with Alzheimer disease neuropathologic change on cognitive decline: Minimal impact of vascular brain injury compared with other combinations.
Sarah M Yasuda, Charles Mock, Kathryn Gauthreaux, Kwun C G Chan, C Dirk Keene, Jessica E Culhane, Yen-Chi Chen, Walter Kukull
Abstract read
In one paragraphArticle in Journal of neuropathology and experimental neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Sarah M YasudaDepartment of Epidemiology, National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, United States.ORCID 0009-0000-6770-1758 Charles MockDepartment of Epidemiology, National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, United States.
Kathryn GauthreauxDepartment of Epidemiology, National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, United States.
Kwun C G ChanDepartment of Epidemiology, National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, United States.
C Dirk KeeneDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States.
Jessica E CulhaneDepartment of Epidemiology, National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, United States.
Yen-Chi ChenDepartment of Epidemiology, National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, United States.
Walter KukullDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, United States.
Funding
Functionally guided adult whole brain cell atlas in human and NHPUM1MH130981 · NIMH · ALLEN INSTITUTE · PI Ed Lein, Hongkui Zeng · 2022 to 2026
$91.9MADRC Consortium for Clarity in ADRD Research Through ImagingU01AG082350 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sarah Biber, BRADFORD C DICKERSON · 2023 to 2026
$90.0MTopographic, cell type and molecular pathway characterization ofAlzheimer's disease using single cell transcriptomics and epigenomicsU19AG060909 · NIA · ALLEN INSTITUTE · PI Michael Hawrylycz · 2020 to 2026
$83.6MTranslational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI CHRISTOPHER DIRK KEENE · 2021 to 2026
$80.4MNational Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8MAging eyes and aging brains in studying alzheimer's disease: Modern ophthalmic data collection in the adult changes in thought (ACT) studyR01AG060942 · NIA · WASHINGTON UNIVERSITY · PI Cecilia Sungmin Lee · 2019 to 2026
$39.4MResearch Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9MResearch Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Teresa Gomez-Isla · 2019 to 2026
$36.5MUCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Mark W Bondi · 2019 to 2026
$34.9MWisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Barbara Brigitta Bendlin · 2019 to 2026
$34.5MResearch Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5MResearch Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Carolyn Wei Zhu · 2020 to 2026
$31.0MNIA-funded ADRCs P20 AG068082NIA-funded ADRCs P30 AG062421NIA-funded ADRCs P30 AG062422NIA-funded ADRCs P30 AG062429NIA-funded ADRCs P30 AG062677NIA-funded ADRCs P30 AG062715NIA-funded ADRCs P30 AG066444NIA-funded ADRCs P30 AG066462NIA-funded ADRCs P30 AG066468NIA-funded ADRCs P30 AG066506NIA-funded ADRCs P30 AG066507NIA-funded ADRCs P30 AG066508NIA-funded ADRCs P30 AG066509NIA-funded ADRCs P30 AG066511NIA-funded ADRCs P30 AG066512NIA-funded ADRCs P30 AG066514NIA-funded ADRCs P30 AG066515NIA-funded ADRCs P30 AG066518NIA-funded ADRCs P30 AG066519NIA-funded ADRCs P30 AG066530NIA-funded ADRCs P30 AG066546NIA-funded ADRCs P30 AG072931NIA-funded ADRCs P30 AG072946NIA-funded ADRCs P30 AG072947NIA-funded ADRCs P30 AG072958NIA-funded ADRCs P30 AG072959NIA-funded ADRCs P30 AG072972NIA-funded ADRCs P30 AG072973NIA-funded ADRCs P30 AG072975NIA-funded ADRCs P30 AG072976NIA-funded ADRCs P30 AG072977NIA-funded ADRCs P30 AG072978NIA-funded ADRCs P30 AG072979NIA-funded ADRCs P30 AG079280NIA-funded ADRCs P30 AG086401NIA/NIH U24 AG072122NIA NIH HHS P20 AG068082NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072959NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072973NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072978NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG086401NIA NIH HHS R01 AG060942NIA NIH HHS R01AG060942NIA NIH HHS R01 AG079280NIA NIH HHS R01 AG082730NIA NIH HHS R01 AG087226NIA NIH HHS R01AG087226NIA NIH HHS R01 AG088656NIA NIH HHS R01AG088656NIA NIH HHS R24 AG073137NIA NIH HHS R24AG073137NIA NIH HHS U01 AG082350NIA NIH HHS U01AG082350NIA NIH HHS U19 AG060909NIA NIH HHS U19AG060909NIA NIH HHS U19 AG066567NIA NIH HHS U19AG066567NIA NIH HHS U24 AG072122NIA NIH HHS U24 AG072458NIA NIH HHS U24AG072458NIH R01AG082730NIMH NIH HHS UM1 MH130981NIMH NIH HHS UM1MH130981NIMH NIH HHS UM1 MH134812NIMH NIH HHS UM1MH134812NINDS NIH HHS U01 NS137484NINDS NIH HHS U01NS137484NINDS NIH HHS U01 NS137500NINDS NIH HHS U01NS137500NINDS NIH HHS U24 NS133945NINDS NIH HHS U24NS133945NINDS NIH HHS U24 NS133949NINDS NIH HHS U24NS133949NINDS NIH HHS U24NS135651
6 · The paper itselfAbstract
We examined cognitive changes associated with several neuropathologic entities, alone and in combination. We studied 808 participants from the National Alzheimer's Coordinating Center to assess associations between neuropathologic diagnoses (from autopsy) and neuropsychologic test scores (trajectories over time for 5 domains: overall cognition, episodic memory, attention, language, executive function). Neuropathologies included: Alzheimer disease neuropathologic change (ADNC), Lewy body disease (LBD), vascular brain injury (VBI), and limbic-predominant age-related TDP43 encephalopathy neuropathologic change (LATE-NC). Using linear mixed-effects models, we examined trajectories of cognitive decline for ADNC alone compared to ADNC plus LBD, VBI, or LATE-NC. We also examined differences between observed trajectories and trajectories that would be expected if the neuropathologic entities exerted their effects independently (additively). ADNC+LBD had worse decline than ADNC alone for 4 of the 5 domains with rate of decline consistent with an additive model for all 4 domains. ADNC+LATE-NC had worse decline than ADNC alone for 3 domains with rate of decline additive for only one and <additive for 2. ADNC+VBI had worse decline than ADNC alone for only one domain, with rate of decline <additive. These findings are relevant for prognostication in clinical practice and for clinical trial design.
Indexed as
Alzheimer DiseaseBrainCerebrovascular TraumaCognition DisordersCognitive DysfunctionAgedAged, 80 and overDisease ProgressionFemaleHumansLewy Body DiseaseMaleNeuropsychological TestsAlzheimer diseaseLewy bodylimbic predominant age-related TDP-43 encephalopathymultiple neuropathologyvascular brain injury
Identifiers
PMID42024684
PMCPMC13374727
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390